

Information pursuant to Section 125 (1) German Stock Corporation Act (AktG) in connection with Section 125 (5) AktG, Article 4 (1) and Table 3 of the Annex to Implementing Regulation (EU) 2018/1212

Type of Information	Description
A. Specification of the message	
1. Unique identifier of the event	APPH052023HV
2. Type of message	Meeting notice of a General Meeting [format pursuant to Implementing Regulation (EU) 2018/1212: NEWM]
B. Specification of the issuer	
1. ISIN	DE000A3CMGM5
2. Name of issuer	APONTIS PHARMA AG
C. Specification of the meeting	
1. Date of the General Meeting	12.05.2023 [format pursuant to Implementing Regulation (EU) 2018/1212: 20230512]
2. Time of the General Meeting	10:00 hrs. (CEST) [format pursuant to Implementing Regulation (EU) 2018/1212: 08:00 UTC]
3. Type of the General Meeting	Virtual Annual General Meeting without the physical attendance of shareholders or their proxy representatives [format pursuant to Implementing Regulation (EU) 2018/1212: GMET]
4. Location of the General Meeting	Virtual General Meeting: https://apontis-pharma.de/hauptversammlung In accordance with the German Stock Corporation Act: Stadttor 1, 40219 Düsseldorf, Germany
5. Record Date	21.04.2023, 00:00 hrs. (CEST) [format pursuant to Implementing Regulation (EU) 2018/1212: 30230420; 22:00 UTC]
6. Uniform Resource Locator (URL)	https://apontis-pharma.de/hauptversammlung
D. Participation in the General Meeting	
D. Participation in the General Meeting – electronic absentee voting	
1. Method of participation by shareholder	Exercising the right to vote through electronic absentee voting per Internet service at https://apontis-pharma.de/hauptversammlung [format pursuant to Implementing Regulation (EU) 2018/1212: EV; ISO 20022: EVOT]
2. Issuer deadline for the notification of participation	05.05.2023, 24:00 hrs. (CEST) [format pursuant to Implementing Regulation (EU) 2018/1212: 20230505; 22:00 UTC]
3. Issuer deadline for voting	12.05.2023, until the time of the closing of voting by the Chairman of the meeting at the virtual General Meeting on 12.05.2023 [format pursuant to Implementing Regulation (EU) 2018/1212: 20230512; until the time of the closing of voting by the Chairman of the Meeting at the virtual General Meeting on 20230512]

D. Participation in the General Meeting – company-appointed proxies	
1. Method of participation by shareholder	<p>Exercising the right to vote by granting authority and issuing instructions to the proxies nominated by the Company</p> <p>[format pursuant to Implementing Regulation (EU) 2018/1212: PX; ISO 20022: PRXY]</p>
2. Issuer deadline for the notification of participation	<p>05.05.2023, 24:00 hrs. (CEST)</p> <p>[format pursuant to Implementing Regulation (EU) 2018/1212: 20230505; 22:00 UTC]</p>
3. Issuer deadline for voting	<p>Granting authority (with voting instructions) to the proxies nominated by the Company</p> <ul style="list-style-type: none"> in writing or in text form by postal mail or email until 11.05.2023, 24:00 hrs (CEST) <p>[format pursuant to Implementing Regulation (EU) 2018/1212: 20230511; 22:00 UTC]</p> <ul style="list-style-type: none"> electronically via the Internet service at https://apontis-pharma.de/hauptversammlung by 12.05.2023, until the time of the closing of voting by the Chairman of the Meeting at the virtual General Meeting on 12.05.2023 <p>[format pursuant to Implementing Regulation (EU) 2018/1212: 20230512; until the time of the closing of voting by the Chairman of the Meeting at the virtual General Meeting on 20230512]</p>
D. Participation in the General Meeting – proxy authorisation	
1. Method of participation by shareholder	<p>Exercising the right to vote through an authorised third party</p> <p>[format pursuant to Implementing Regulation (EU) 2018/1212: PX; ISO 20022: PRXY]</p>
2. Issuer deadline for the notification of participation	<p>05.05.2023, 24:00 hrs. (CEST)</p> <p>[format pursuant to Implementing Regulation (EU) 2018/1212: 20230505; 22:00 UTC]</p>
3. Issuer deadline for voting	<p>Exercising of voting rights via electronic absentee voting by the proxy via Internet service at https://apontis-pharma.de/hauptversammlung:</p> <ul style="list-style-type: none"> 12.05.2023, until the time of the closing of voting by the Chairman of the Meeting at the virtual General Meeting on 12.05.2023 <p>[format pursuant to Implementing Regulation (EU) 2018/1212: 20230512; until the time of the closing of voting by the Chairman of the Meeting at the virtual General Meeting on 20230512]</p> <p>Exercising of voting rights by the proxy through granting sub-proxies and issuing instructions to the proxies appointed by the Company:</p> <ul style="list-style-type: none"> in writing or in text form by postal mail or email until 11.05.2023, 24:00 hrs (CEST) <p>[format pursuant to Implementing Regulation (EU) 2018/1212: 20230511; 22:00 UTC]</p> <ul style="list-style-type: none"> electronically via the Internet service at https://apontis-pharma.de/hauptversammlung by 12.05.2023, until the time of the closing of voting by the Chairman of the Meeting at the virtual General Meeting on 12.05.2023 <p>[format pursuant to Implementing Regulation (EU) 2018/1212: 20230512; until the time of the closing of voting by the Chairman of the Meeting at the virtual General Meeting on 20230512]</p>

E. Agenda	
E. Agenda – item 1	
1. Unique identifier of the agenda item	1
2. Title of the agenda item	Presentation of the approved annual financial statements of APONTIS PHARMA AG as of 31 December 2022 and the approved consolidated financial statements as of 31 December 2022 and the group management report for the financial year 2022 as well as the report of the Supervisory Board for the financial year 2022
3. Uniform Resource Locator (URL) of the materials	https://apontis-pharma.de/hauptversammlung
4. Vote	
5. Alternative voting options	
E. Agenda – item 2	
1. Unique identifier of the agenda item	2
2. Title of the agenda item	Resolution on the discharge of the members of the Executive Board for the financial year 2022
3. Uniform Resource Locator (URL) of the materials	https://apontis-pharma.de/hauptversammlung
4. Vote	Binding vote [format pursuant to Implementing Regulation (EU) 2018/1212: BV; ISO 20022: BNDG]
5. Alternative voting options	Vote in favour, Vote against, Abstention [format pursuant to Implementing Regulation (EU) 2018/1212: VF, VA, AB; ISO 20022: CFOR, CAGS, ABST]
E. Agenda – item 3	
1. Unique identifier of the agenda item	3
2. Title of the agenda item	Resolution on the discharge of the members of the Supervisory Board for the financial year 2022
3. Uniform Resource Locator (URL) of the materials	https://apontis-pharma.de/hauptversammlung
4. Vote	Binding vote [format pursuant to Implementing Regulation (EU) 2018/1212: BV; ISO 20022: BNDG]
5. Alternative voting options	Vote in favour, Vote against, Abstention [format pursuant to Implementing Regulation (EU) 2018/1212: VF, VA, AB; ISO 20022: CFOR, CAGS, ABST]

E. Agenda – item 4	
1. Unique identifier of the agenda item	4
2. Title of the agenda item	Election of the auditor and the group auditor for the financial year 2023
3. Uniform Resource Locator (URL) of the materials	https://apontis-pharma.de/hauptversammlung
4. Vote	Binding vote [format pursuant to Implementing Regulation (EU) 2018/1212: BV; ISO 20022: BNDG]
5. Alternative voting options	Vote in favour, Vote against, Abstention [format pursuant to Implementing Regulation (EU) 2018/1212: VF, VA, AB; ISO 20022: CFOR, CAGS, ABST]
E. Agenda – item 5.1	
1. Unique identifier of the agenda item	5.1
2. Title of the agenda item	Resolutions on amendments to the Articles of Association in connection with virtual general meetings - Resolution on the amendment of § 16 of the Articles of Association to authorise the Executive Board to hold virtual general meetings
3. Uniform Resource Locator (URL) of the materials	https://apontis-pharma.de/hauptversammlung
4. Vote	Binding vote [format pursuant to Implementing Regulation (EU) 2018/1212: BV; ISO 20022: BNDG]
5. Alternative voting options	Vote in favour, Vote against, Abstention [format pursuant to Implementing Regulation (EU) 2018/1212: VF, VA, AB; ISO 20022: CFOR, CAGS, ABST]
E. Agenda – item 5.2	
1. Unique identifier of the agenda item	5.2
2. Title of the agenda item	Resolutions on amendments to the Articles of Association in connection with virtual Annual General Meetings - 5.2 Resolution on the amendment of § 16 of the Articles of Association to enable the participation of Supervisory Board members by way of video and audio transmission
3. Uniform Resource Locator (URL) of the materials	https://apontis-pharma.de/hauptversammlung
4. Vote	Binding vote [format pursuant to Implementing Regulation (EU) 2018/1212: BV; ISO 20022: BNDG]
5. Alternative voting options	Vote in favour, Vote against, Abstention [format pursuant to Implementing Regulation (EU) 2018/1212: VF, VA, AB; ISO 20022: CFOR, CAGS, ABST]

F. Specification of the deadlines regarding the exercise of other shareholders rights	
F. Shareholder right – requests for additions to the agenda pursuant to section 122 (2) of the German Stock Corporation Act (AktG)	
1. Object of deadline	Submission of requests for additions to the agenda
2. Applicable issuer deadline	17.04.2023, 24:00 hrs (CEST) (time of receipt decisive) [format pursuant to Implementing Regulation (EU) 2018/1212: 20230417; 22:00 UTC]
F. Shareholder right – submission of counter-motions pursuant to section 126 (1) of the German Stock Corporation Act (AktG)	
1. Object of deadline	Submission of counter-motions to specific items on the agenda to be made available to the other shareholders prior to the General Meeting
2. Applicable issuer deadline	27.04.2023, 24:00 hrs. (CEST) (receipt is decisive) [format pursuant to Implementing Regulation (EU) 2018/1212: 20230427; 22:00 UTC].
F. Shareholder right – submission of proposals for election pursuant to section 127 of the German Stock Corporation Act (AktG)	
1. Object of deadline	Submission of election proposals for the election of Supervisory Board members or auditors to be made available to the other shareholders prior to the General Meeting
2. Applicable issuer deadline	27.04.2023, 24:00 hrs. (CEST) (receipt is decisive) [format pursuant to Implementing Regulation (EU) 2018/1212: 20230427; 22:00 UTC].
F. Shareholder right – submission of statements pursuant to section 130a (1) to (4) of the German Stock Corporation Act (AktG)	
1. Object of deadline	Submission of statements on the items of the agenda in text form or in video format by way of electronic communication via the Internet service at https://apontis-pharma.de/hauptversammlung
2. Applicable issuer deadline	06.05.2023, 24:00 hrs. (CEST) (receipt is decisive) [format pursuant to Implementing Regulation (EU) 2018/1212: 20230506; 22:00 UTC]
F. Shareholder right – right to speak at the General Meeting pursuant to section 130a (5) of the German Stock Corporation Act (AktG) (including the right to propose motions and nominations pursuant to section 118a (1) sentence 2 no. 3 of the German Stock Corporation Act (AktG) and the right to request information pursuant to section 131 (1) of the German Stock Corporation Act (AktG))	
1. Object of deadline	Right to speak at the General Meeting by way of video communication via the Internet service at https://apontis-pharma.de/hauptversammlung . The right to speak also includes, in particular, the right to submit motions and election proposals pursuant to section 118a (1) sentence 2 no. 3 of the German Stock Corporation Act (AktG), as well as the right to request information pursuant to section 131 (1) of the German Stock Corporation Act (AktG)
2. Applicable issuer deadline	12.05.2023; during the General Meeting on 12.05.2023 as directed by the Chairman of the Meeting. [format pursuant to Implementing Regulation (EU) 2018/1212: 20230512; during the General Meeting on 20230512 as directed by the Chairman of the Meeting]

F. Shareholder right – submission of the request pursuant to section 131 (4) sentences 1, 2 of the German Stock Corporation Act (AktG)	
1. Object of deadline	Submission of the request pursuant to section 131 (4) sentences 1, 2 of the German Stock Corporation Act (AktG) by way of electronic communication via the Internet service at https://apontis-pharma.de/hauptversammlung
2. Applicable issuer deadline	12.05.2023; from the opening of the General Meeting on 12.05.2023 until the termination of this right by the Chairman of the Meeting [format pursuant to Implementing Regulation (EU) 2018/1212: 20230512; from the opening of the General Meeting on 20230512 until the termination of this right by the Chairman of the Meeting]
F. Shareholder right – submission of the request pursuant to section 131 (5) sentences 1, 2 of the German Stock Corporation Act (AktG)	
1. Object of deadline	Submission of the request pursuant to section 131 (5) sentences 1, 2 of the German Stock Corporation Act (AktG) by way of electronic communication via the Internet service at https://apontis-pharma.de/hauptversammlung
2. Applicable issuer deadline	12.05.2023; from the opening of the General Meeting on 12.05.2023 until the closing of the General Meeting by the Chairman of the Meeting [format pursuant to Implementing Regulation (EU) 2018/1212: 20230512; from the opening of the General Meeting on 20230512 until the closing of the General Meeting by the Chairman of the Meeting]
F. Shareholder right – right of filing of objections pursuant to section 118a (1) sentence 2 no. 8 of the German Stock Corporation Act (AktG)	
1. Object of deadline	Filing of objections against resolutions of the General Meeting by way of electronic communication via the Internet service at https://apontis-pharma.de/hauptversammlung
2. Applicable issuer deadline	12.05.2023, from the opening of the General Meeting on 12.05.2023 until the closing of the meeting by the Chairman of the meeting. [format pursuant to Implementing Regulation (EU) 2018/1212: 20230512; from the opening of the General Meeting on 20230512 until the closing of the meeting by the Chairman of the Meeting].